This Is Precision in Practice

The iRhythm® service featuring Zio® ECG monitor - say hello to a comprehensive approach to cardiac monitoring.

Easy-to-wear monitor.1-3 Outstanding patient compliance.4-6 Exceptional accuracy.7-9 With our end-to-end service, we've completely changed the world of cardiac monitoring.10-15

Learn more about Zio monitoring services

Precision is at the heart of iRhythm

iRhythm continually strives to perfect the cardiac monitoring experience. Our patient-friendly1-3 Zio ECG monitor and end-to-end service deliver trustworthy data, enabling accurate diagnoses from the start.7-15

Improved wear experience

Zio ECG montiors are designed to be comfortable16-18 and easy to wear1-3 for better patient satisfaction and compliance.16-18

Outstanding patient compliance

Near-perfect patient compliance19-21 generates high-quality, actionable data10-15

Remarkable clinical outcomes

Compared to other monitoring services, including long-term continuous monitors (LTCMs), the Zio LTCM service is a continuous, uninterrupted cardiac monitor associated with:

 

Highest diagnostic yield10-15

Lowest likelihood of retesting10-15

More than a monitor

The iRhythm service is transforming cardiac monitoring end to end.

How the Zio service works.

Physician prescribes the Zio monitoring service. A Zio ambulatory ECG monitor is applied to the patient in-clinic or at home.
Patient wears the Zio cardiac monitor, then mails it back to iRhythm.
iRhythm analyzes the data.
Physician receives a high-quality, actionable end-of-wear report in ZioSuite® or EHR system.​22-25

Interested in iRhythm Zio™ ambulatory ECG services please contact your Senko Medical representative.

Incredible 99% physician agreement with end-of-wear reports

The iRhythm monitoring service combines the only FDA-cleared, deep-learned algorithm curated and verified by a certified cardiographic technicians (CCTs) 22-25 to generate reports with 99% physician agreement,26-28 which can lead to an accurate and timely diagnosis.7-15

~8 million patients analyzed29-30

Over 1.5 billion hours of curated heartbeat data31-32

Comprehensive reports verified by CCTs22-25

Zio monitor

Zio® monitor IFU

Learn how to apply and use the Zio monitor.

Download Instructions for Use
Download ZioSuite® Reference Guide
  1. Battisti et al. Abstract 4141717: Feasibility of point-of-wear patient satisfaction surveys to validate patient-centered product enhancements: results from over 300,000 patients for long-term ambulatory cardiac monitoring. Circulation. 2024;150:A4141717. doi:10.1161/circ.150.suppl_1.4141717. https://www.ahajournals.org/doi/abs/10.1161/circ.150.suppl_1.4141717
  2. Data on file. iRhythm Technologies, 2024
  3. Based on the US market data.
  4. Data on file. iRhythm Technologies, 2022.
  5. Based on the US data.
  6. Zio service provides continuous, uninterrupted recording and a comprehensive end-of-wear report.
  7. Data on file. iRhythm Technologies, 2023.
  8. Based on the US market data using Zio ECG monitors.
  9. Zio service provides continuous, uninterrupted recording and a comprehensive end-of-wear report.
  10. Reynolds et al. Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries. Am Heart J. 2024;269:25–34. https://doi.org/10.1016/j.ahj.2023.12.002
  11. A specified arrhythmia refers to an arrhythmia encounter diagnosis as per Hierarchical Condition Categories (HCC) 96.
  12. Based on previous generation Zio XT device data. Zio monitor utilizes the same operating principles and ECG algorithm. Additional data on file.
  13. Zio LTCM service refers to Zio XT and Zio monitor service.
  14. Contraindications: Do not use the Zio monitor for critical care patients or for patients with symptomatic episodes where instance variations in cardiac performance could result in immediate danger to the patients or when real-time or in-patient monitoring should be prescribed. (Refer to the Zio monitor Instructions for Use for the full list of contraindications.)
  15. Zio monitor and ZEUS are Japan PMDA approval.
  16. Zio monitor Instructions for Use. iRhythm Technologies, 2023.
  17. Battisti et al. Abstract 4141717: Feasibility of point-of-wear patient satisfaction surveys to validate patient-centered product enhancements: results from over 300,000 patients for long-term ambulatory cardiac monitoring. Circulation. 2024;150:A4141717. doi:10.1161/circ.150.suppl_1.4141717. https://www.ahajournals.org/doi/abs/10.1161/circ.150.suppl_1.4141717
  18. Based on US data.
  19. Data on file. iRhythm Technologies, 2022.
  20. Based on the US data.
  21. Zio service provides continuous, uninterrupted recording and a comprehensive end-of-wear report.
  22. Data on file. iRhythm Technologies, 2020.
  23. Hannun et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. Nat Med. 2019;25:65-69. https://doi.org/10.1038/s41591-018-0268-3
  24. Deep learned algorithm is only available in the United States, European Union, Switzerland, United Kingdom, and Japan. ​
  25. FDA 510K clearance, CE mark, UKCA mark, and PMDA-approval.
  26. 99% of physicians agree with the comprehensive end-of-wear report. Based on a review of all online Zio XT, Zio monitor, and Zio AT end-of-wear reports. Data on file. iRhythm Technologies, 2023.
  27. Based on the US data.
  28. Zio service provides continuous, uninterrupted recording and a comprehensive end-of-wear report.
  29. Data on file. iRhythm Technologies. 2023.
  30. Based on the US data using Zio® ECG monitors.
  31. Data on file. iRhythm Technologies, 2023.
  32. Based on the US and UK data using Zio® ECG monitors.

WEB0176.01